Teresa Troiani

List of Publications by Citations

99 papers	2,994 citations	31 h-index	53 g-index
104 ext. papers	3,440 ext. citations	6.4 avg, IF	4.61 L-index

#	Paper	IF	Citations
99	Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. *Clinical Cancer Research*, **2004**, 10, 784-93	12.9	309
98	Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. *Clinical Cancer Research*, **2003**, 9, 1546-56	12.9	229
97	Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). *Clinical Cancer Research* , **2002**, 8, 3250-8	12.9	164
96	Increased TGF-as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. *Clinical Cancer Research*, **2013**, 19, 6751-65	12.9	111
95	SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer. *Clinical Cancer Research*, **2015**, 21, 4686-97	12.9	93
94	Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. *Clinical Cancer Research*, **2013**, 19, 3508-19	12.9	88
93	Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. *International Journal of Cancer*, **2001**, 93, 172-8	7.5	79
92	Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. *Oncologist*, **2006**, 11, 274-84	5.7	78
91	Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. *Cancer Treatment Reviews*, **2017**, 53, 61-69	14.4	77
90	Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. *Clinical Cancer Research*, **2014**, 20, 3775-86	12.9	76
89	Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. *Endocrine-Related Cancer*, **2005**, 12 Suppl 1, S159-71	5.7	76
88	Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. *World Journal of Gastroenterology*, **2017**, 23, 4675-4688	5.6	70
87	Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. *International Journal of Cancer*, **2013**, 133, 2089-101	7.5	70
86	Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. *Clinical Cancer Research*, **2010**, 16, 4990-5001	12.9	70
85	Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. *ESMO Open*, **2016**, 1, e000088	6	69
84	Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. *World Journal of Gastroenterology*, **2016**, 22, 6345-61	5.6	69
83	Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. *Journal of Cellular Physiology*, **2006**, 208, 344-53	7	54

82	Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. *Clinical Cancer Research*, **2015**, 21, 2975-83	12.9	51
81	Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells. *Oncotarget*, **2016**, 7, 4265-78	3.3	51
80	The use of xenograft models for the selection of cancer treatments with the EGFR as an example. *Critical Reviews in Oncology/Hematology*, **2008**, 65, 200-11	7	50
79	Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. *Clinical Cancer Research*, **2006**, 12, 7099-107	12.9	47
78	A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. *Angiogenesis*, **2012**, 15, 141-50	10.6	46
77	AXL is an oncotarget in human colorectal cancer. *Oncotarget*, **2015**, 6, 23281-96	3.3	45
76	Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. *Expert Opinion on Biological Therapy*, **2013**, 13, 241-55	5.4	44
75	Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. *Journal of Experimental and Clinical Cancer Research*, **2019**, 38, 41	12.8	37
74	Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. *Molecular Cancer Therapeutics*, **2006**, 5, 1883-94	6.1	37
73	Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity. *Clinical Cancer Research*, **2003**, 9, 866-71	12.9	37
72	Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model. *Clinical Cancer Research*, **2007**, 13, 6450-8	12.9	36
71	Role and targeting of anaplastic lymphoma kinase in cancer. *Molecular Cancer*, **2018**, 17, 30	42.1	34
70	Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. *PLoS ONE*, **2011**, 6, e28841	3.7	34
69	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. *Oncologist*, **2018**, 23, 1178-1187	5.7	31
68	EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. *Molecular Cancer Therapeutics* , **2019**, 18, 845-855	6.1	30
67	Metabolomic approach for a rapid identification of natural products with cytotoxic activity against human colorectal cancer cells. *Scientific Reports*, **2018**, 8, 5309	4.9	26
66	Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. *Oncotarget*, **2017**, 8, 23020-23032	3.3	26
65	Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. *Clinical Cancer Research*, **2005**, 11, 1268-76	12.9	25

64	Laparoscopic treatment of abdominal unicentric castleman's disease: a case report and literature review. *BMC Surgery*, **2017**, 17, 38	2.3	24
63	Emerging VEGF-receptor inhibitors for colorectal cancer. *Expert Opinion on Emerging Drugs*, **2013**, 18, 25-37	3.7	24
62	Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors. *Lung Cancer*, **2011**, 71, 283-90	5.9	24
61	Metformin in lung cancer: rationale for a combination therapy. *Expert Opinion on Investigational Drugs*, **2013**, 22, 1401-9	5.9	22
60	Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells. *Molecular Cancer Therapeutics*, **2008**, 7, 1698-707	6.1	22
59	Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. *Expert Opinion on Investigational Drugs*, **2014**, 23, 809-21	5.9	21
58	Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. *Oncotarget*, **2017**, 8, 68305-68316	3.3	20
57	How we treat metastatic colorectal cancer. *ESMO Open*, **2020**, 4, e000813	6	20
56	Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC. *Journal of Experimental and Clinical Cancer Research*, **2019**, 38, 178	12.8	19
55	Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. *Journal of Thoracic Oncology*, **2018**, 13, 810-820	8.9	19
54	Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. *ESMO Open*, **2017**, 2, e000177	6	19
53	Use of Rituximab in NHL Malt Type Pregnant in I□Trimester for Two Times. *Open Medicine (Poland)*, **2019**, 14, 757-760	2.2	19
52	Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?. *Cancer Treatment Reviews*, **2020**, 86, 102023	14.4	19
51	Cancer- and Non-cancer Related Chronic Pain: From the Physiopathological Basics to Management. *Open Medicine (Poland)*, **2019**, 14, 761-766	2.2	18
50	Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer. *Expert Opinion on Investigational Drugs*, **2012**, 21, 949-59	5.9	18
49	Resistance mechanisms of tumour cells to EGFR inhibitors. *Clinical and Translational Oncology*, **2009**, 11, 270-5	3.6	17
48	Antiangiogenic drugs in non-small cell lung cancer treatment. *Current Opinion in Oncology*, **2006**, 18, 151-52	4.2	17
47	Differential Diagnosis: Retroperitoneal Fibrosis and Oncological Diseases. *Open Medicine (Poland)*, **2018**, 15, 22-26	2.2	14

46	Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. *Clinical Cancer Research*, **2015**, 21, 4153-64	12.9	13
45	Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models. *Journal of Experimental and Clinical Cancer Research*, **2019**, 38, 236	12.8	12
44	Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) in the Elderly and the Importance of Sport Activity Training. *International Journal of Environmental Research and Public Health*, **2020**, 17,	4.6	12
43	Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation. *Oncotarget*, **2017**, 8, 67592-67604	3.3	11
42	Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literature. *ESMO Open*, **2019**, 4, e000551	6	11
41	Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?. *Therapeutic Advances in Medical Oncology*, **2013**, 5, 51-72	5.4	10
40	Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass. *World Journal of Surgical Oncology*, **2007**, 5, 42	3.4	9
39	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. *European Journal of Cancer*, **2020**, 138, 1-10	7.5	9
38	Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells. *Cancers*, **2019**, 11,	6.6	6
37	Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania 'Luigi Vanvitelli'. *ESMO Open*, **2020**, 5,	6	6
36	Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. *Journal of Experimental and Clinical Cancer Research*, **2021**, 40, 15	12.8	6
35	Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. *European Journal of Cancer*, **2021**, 157, 250-258	7.5	6
34	Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice. *Medical Oncology*, **2017**, 34, 186	3.7	5
33	Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells. *Oncotarget*, **2017**, 8, 82773-82783	3.3	5
32	Critical appraisal of the use of regorafenib in the management of colorectal cancer. *Cancer Management and Research*, **2013**, 5, 49-55	3.6	5
31	Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells. *Oncotarget*, **2018**, 9, 19273-19282	5.3	5
30	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.. *Frontiers in Immunology*, **2022**, 13, 804597	8.4	4
29	Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment. *Targeted Oncology*, **2006**, 1, 123-129	5	3

28	Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. *Expert Opinion on Drug Discovery*, **2007**, 2, 335-48	6.2	3
27	Baseline IFN- and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients. *Scientific Reports*, **2020**, 10, 17626	4.9	3
26	Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer. *ESMO Open*, **2019**, 4, e000519	6	3
25	Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients. *British Journal of Cancer*, **2020**, 122, 1782-1790	8.7	3
24	Optimal treatment strategy in KRAS wild type (wt) metastatic colorectal cancer (mCRC): Cetuximab plus FOLFIRI followed by FOLFOX4 with or without cetuximab-The Capri trial from the Gruppo Oncologico DelllItalia Meridionale (GOIM).. *Journal of Clinical Oncology*, **2013**, 31, e14565-e14565	2.2	2
23	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. *Journal of Clinical Oncology*, **2015**, 33, TPS3634-TPS3634	2.2	2
22	Final results from the CAVE (cetuximab rechallenge plus avelumab) mCRC phase II trial: Skin toxicity as a predictor of clinical activity.. *Journal of Clinical Oncology*, **2021**, 39, 3578-3578	2.2	2
21	Dual inhibition of TGF and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype. *Medical Oncology*, **2021**, 38, 24	3.7	2
20	Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data. *Clinical Colorectal Cancer*, **2021**, 20, 227-235	3.8	2
19	Genetic Landscape of Primary Versus Metastatic Colorectal Cancer: to What Extent Are They Concordant?. *Current Colorectal Cancer Reports*, **2015**, 11, 217-224	1	1
18	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. *Journal of Clinical Oncology*, **2015**, 33, TPS789-TPS789	2.2	1
17	Anorectal and Genital Mucosal Melanoma: Diagnostic Challenges, Current Knowledge and Therapeutic Opportunities of Rare Melanomas.. *Biomedicines*, **2022**, 10,	4.8	1
16	NMR Profiling of Identifies Cytotoxic Compounds against Cetuximab-Resistant Colon Cancer Cell Lines. *Molecules*, **2021**, 26,	4.8	1
15	Hypothalamic-Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies. *Cancers*, **2021**, 13,	6.6	1
14	Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series.. *Healthcare (Switzerland)*, **2022**, 10,	3.4	1
13	Treatment of Cutaneous Melanoma Harboring SMO p.Gln216Arg Mutation with Imiquimod: An Old Drug with New Results. *Journal of Personalized Medicine*, **2021**, 11,	3.6	0
12	Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial.. *Journal of Experimental and Clinical Cancer Research*, **2022**, 41, 109	12.8	0
11	Immunotherapy in advanced anal cancer: Is the beginning of a new era?. *Cancer Treatment Reviews*, **2022**, 105, 102373	14.4	0

List of Publications

10	Optimization of the Development of Old and New EGFR and MAP Kinase Inhibitors for Colorectal Cancer. *Current Colorectal Cancer Reports*, **2014**, 10, 279-287	1
9	Predictive biomarkers to anti-EGF receptor inhibitors in the treatment of metastatic colorectal cancer. *Colorectal Cancer*, **2014**, 3, 299-308	0.8
8	Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity. *Current Cancer Therapy Reviews*, **2007**, 3, 236-241	0.4
7	Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy. *Current Cancer Therapy Reviews*, **2007**, 3, 117-126	0.4
6	Correlation of 12-weeks decrease of CA19.9 with overall response rate (ORR) and progression-free survival (PFS) in advanced pancreatic cancer (APC) patients (pts) treated with first-line nab-paclitaxel (Nab-P) and gemcitabine (G).. *Journal of Clinical Oncology*, **2014**, 32, e15256-e15256	2.2
5	The pretreatment neutrophil-lymphocyte ratio (NLR) as a predictor of outcome in a cohort of metastatic pancreatic cancer patients treated with nab-paclitaxel and gemcitabine.. *Journal of Clinical Oncology*, **2015**, 33, e15224-e15224	2.2
4	Trastuzumab Resistance in Breast Cancer **2011**, 51-60	
3	Clinical results with EGFR inhibitors in colorectal cancer **2012**, 44-59	
2	Incidence and prognostic significance of HER2 overexpression in gastric cancer (GC): A monoinstitutional retrospective analysis.. *Journal of Clinical Oncology*, **2014**, 32, 160-160	2.2
1	Current Landscape and Open Questions on Adjuvant Therapies in Melanoma. *Dermatology Practical and Conceptual*, **2021**, 11, e2021165S	1.5